Lyon Street Capital LLC bought a new position in shares of Immunomedics, Inc. (NASDAQ:IMMU) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 150,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,097,000. Lyon Street Capital LLC owned 0.10% of Immunomedics as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. FMR LLC grew its holdings in Immunomedics by 260.6% during the 2nd quarter. FMR LLC now owns 5,496,851 shares of the biopharmaceutical company’s stock worth $48,537,000 after acquiring an additional 3,972,388 shares during the period. State Street Corp grew its holdings in Immunomedics by 37.2% during the 2nd quarter. State Street Corp now owns 4,818,847 shares of the biopharmaceutical company’s stock worth $42,549,000 after acquiring an additional 1,305,298 shares during the period. Vanguard Group Inc. grew its holdings in Immunomedics by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,522,091 shares of the biopharmaceutical company’s stock worth $39,930,000 after acquiring an additional 105,558 shares during the period. Farallon Capital Management LLC grew its holdings in Immunomedics by 1.7% during the 2nd quarter. Farallon Capital Management LLC now owns 4,227,500 shares of the biopharmaceutical company’s stock worth $37,329,000 after acquiring an additional 72,500 shares during the period. Finally, Palo Alto Investors LLC acquired a new stake in Immunomedics during the 2nd quarter worth $26,582,000. 76.32% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have commented on IMMU shares. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a report on Wednesday, October 4th. Jefferies Group set a $11.00 price target on shares of Immunomedics and gave the company a “buy” rating in a report on Thursday, August 17th. ValuEngine lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a report on Monday. Finally, BidaskClub raised shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Immunomedics currently has a consensus rating of “Buy” and an average target price of $15.33.
In related news, Director Venbio Select Advisor Llc bought 1,150,000 shares of Immunomedics stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average cost of $10.39 per share, with a total value of $11,948,500.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Behzad Aghazadeh bought 1,325,000 shares of Immunomedics stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average cost of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. 6.60% of the stock is owned by insiders.
WARNING: This piece was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/12/06/lyon-street-capital-llc-takes-2-10-million-position-in-immunomedics-inc-immu.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.